title: Prominent neuroleptic sensitivity in a case of early-onset Alzheimer disease due to presenilin-1 G206A mutation.
abstract: OBJECTIVE
  We describe atypical motor and cognitive features in a case of familial Alzheimer disease (FAD) due to presenilin-1 (PS-1) mutation.
  
  
  BACKGROUND
  Extrapyramidal signs (EPS) typically are a late-presenting feature of sporadic Alzheimer disease (AD), but relatively little data are available regarding EPS in FAD.
  
  
  METHODS
  A 59-year-old, right-handed man of Caribbean-Hispanic descent underwent brain imaging studies, laboratory tests for AD, and serial neurologic and neuropsychologic evaluations.
  
  
  RESULTS
  The patient presented with recent-onset delusional ideation associated with cognitive decline. Prominent EPS developed soon after initiation of an atypical neuroleptic agent. Neuropsychologic evaluation revealed global cognitive deficits; he was found to be a carrier of a PS-1 point mutation at position G206A. EPS resolved completely after discontinuing the neuroleptic agent and coincided with improved motor speed, set initiation, and verbal fluency.
  
  
  CONCLUSIONS
  Severe neuroleptic sensitivity and associated deficits of cognitive speed occurred in response to a dopaminergic antagonist agent; both responded readily to withdrawal of the offending agent. Patients with PS-1 AD may be at substantially increased risk of neuroleptic-induced EPS. That feature underscores the heterogeneity of the FAD clinical phenotype.
authors.affiliation: Memory Disorders Clinic, Veterans Affairs New York Harbor Healthcare System, New York, NY 10010, USA. steven.cercy@va.gov
authors.forename: Steven P
authors.initials: SP
authors.lastname: Cercy
authors.forename: Martin J
authors.initials: MJ
authors.lastname: Sadowski
authors.forename: Thomas
authors.initials: T
authors.lastname: Wisniewski
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy* / Q000235:genetics* / Q000503:physiopathology; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D004252:DNA Mutational Analysis; D004342:Drug Hypersensitivity / Q000209:etiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010375:Pedigree; D017354:Point Mutation / Q000235:genetics*; D053764:Presenilin-1 / Q000235:genetics*
chemical_list: D014150:Antipsychotic Agents; D053764:Presenilin-1
references.citation: Neurology. 2000 May 23;54(10):1965-71
references.pmid: 10822438
references.citation: Neurology. 2005 Jul 26;65(2):323-5
references.pmid: 16043812
references.citation: Int J Geriatr Psychiatry. 2002 Jul;17(7):649-51
references.pmid: 12112163
references.citation: J Pharmacol Exp Ther. 1988 Nov;247(2):661-70
references.pmid: 2460616
references.citation: Hum Mol Genet. 1998 Sep;7(9):1507-9
references.pmid: 9700207
references.citation: J Neurosci. 2007 Jun 6;27(23):6174-84
references.pmid: 17553989
references.citation: JAMA. 2001 Nov 14;286(18):2257-63
references.pmid: 11710891
references.citation: Acta Neuropathol. 2002 Dec;104(6):637-48
references.pmid: 12410385
references.citation: Psychiatry Res. 2002 Dec 30;116(3):163-72
references.pmid: 12477600
references.citation: Arch Neurol. 1998 Oct;55(10):1335-40
references.pmid: 9779662
references.citation: Neurology. 2005 Feb 8;64(3):509-13
references.pmid: 15699383
references.citation: Biol Psychiatry. 1998 Oct 15;44(8):765-74
references.pmid: 9798081
references.citation: J Neurosci. 1995 Jan;15(1 Pt 2):821-9
references.pmid: 7823183
references.citation: Am J Psychiatry. 1996 Apr;153(4):466-76
references.pmid: 8599393
references.citation: J Clin Psychopharmacol. 1999 Aug;19(4):322-8
references.pmid: 10440459
references.citation: Acta Neuropathol. 2000 Aug;100(2):145-52
references.pmid: 10963361
references.citation: J Neurol Sci. 2007 Sep 15;260(1-2):33-7
references.pmid: 17459416
references.citation: Brain Pathol. 2000 Jul;10(3):378-84
references.pmid: 10885656
references.citation: J Neurol Neurosurg Psychiatry. 2001 Dec;71(6):777-9
references.pmid: 11723200
references.citation: Lancet Neurol. 2003 Oct;2(10):605-13
references.pmid: 14505582
references.citation: Eur J Neurol. 2004 Oct;11(10):663-9
references.pmid: 15469450
references.citation: Ann Neurol. 2005 Mar;57(3):429-34
references.pmid: 15732120
references.citation: J Clin Psychiatry. 2005 May;66(5):633-7
references.pmid: 15889951
references.citation: Brain. 2000 May;123 ( Pt 5):894-907
references.pmid: 10775535
references.citation: Mayo Clin Proc. 1999 Aug;74(8):835-7
references.pmid: 10473363
references.citation: Brain. 1999 Aug;122 ( Pt 8):1449-68
references.pmid: 10430831
references.citation: Am J Geriatr Psychiatry. 2000 Summer;8(3):226-31
references.pmid: 10910421
references.citation: J Neurol Neurosurg Psychiatry. 2006 Jun;77(6):796-8
references.pmid: 16705205
references.citation: J Geriatr Psychiatry Neurol. 2006 Dec;19(4):195-201
references.pmid: 17085757
references.citation: Neuropsychopharmacology. 2004 Jun;29(6):1190-202
references.pmid: 15010698
references.citation: Neurology. 2003 May 27;60(10):1586-90
references.pmid: 12771246
references.citation: Neurology. 2005 Dec 27;65(12):1863-72
references.pmid: 16237129
references.citation: Psychopharmacology (Berl). 2007 May;191(4):1027-9
references.pmid: 17333131
references.citation: Arch Neurol. 2001 Mar;58(3):466-72
references.pmid: 11255451
references.citation: J Clin Psychopharmacol. 2006 Apr;26(2):192-7
references.pmid: 16633151
references.citation: Neuropsychopharmacology. 2007 Jan;32(1):171-9
references.pmid: 16841077
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2003 Feb;27(1):103-8
references.pmid: 12551731
references.citation: Neurology. 1994 Dec;44(12):2300-7
references.pmid: 7991116
references.citation: Lancet. 1998 Apr 4;351(9108):1032-3
references.pmid: 9546516
references.citation: Arch Neurol. 2003 Jun;60(6):884-8
references.pmid: 12810495